Efdamrofusp alfa 是一种双特异性融合蛋白。Efdamrofusp alfa 能够中和 VEGF 亚型和 C3b/C4b。Efdamrofusp alfa 可用于新生血管性年龄相关性黄斑变性 (nAMD) 和其他与补体相关的眼部疾病的研究。
| 生物活性 | Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing bothVEGFisoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions[1]. |
体外研究
(In Vitro) | Efdamrofusp alfa（0.135 mg/mL；0、6、12 或 24 小时）抑制内皮细胞迁移和管形成[1]。
Efdamrofusp alfa (0-1000 μg/mL) 在体外抑制补体激活[1]。
Cell Migration Assay[1] | Cell Line: | Human primary umbilical vein endothelial cell (HUVEC) | | Concentration: | 0.135 mg/mL | | Incubation Time: | 0, 6, 12, or 24 h | | Result: | Showed a 20.91% reduction in migration. |
|
体内研究
(In Vivo) | Efdamrofusp alfa（13.5 μg；3 天）在激光诱导的 CNV 小鼠模型中抑制补体系统的激活[1]。
Efdamrofusp alfa（1.35 mg；单次玻璃体内注射）在非人灵长类动物激光诱导的 CNV 模型中显示出良好的安全性和抗血管生成功效[1]。
| Animal Model: | C57BL/6J mice[1] | | Dosage: | 13.5 μg; 13.0 μg | | Administration: | 3 days; 7days | | Result: | Significantly reduced C3d deposition.
Reduced vascular leakage at 7 days after laser-induced injury.
Significantly suppressed CNV formation 7 days after laser-induced injury.
Reduced the concentrations of vitreous VEGF-A. |
| Animal Model: | Rhesus monkeys[1] | | Dosage: | 1.35 mg | | Administration: | Single intravitreal injection | | Result: | Decreased the CNV leakage at 14 and 28 days and effectively reduced CNV volume 28 days. |
|
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
